(firstQuint)Doripenem in the Treatment of Ventilator-Associated Pneumonia.

 Doripenem is an antibiotic medication not yet approved by the US FDA.

 This is a phase 3, multicenter, prospective, randomized, open-label study of doripenem versus comparator to assess the effectiveness and safety of doripenem in the treatment of VAP in adult patients.

 The study consists of screening phase, open-label treatment phase, and follow-up.

 The treatment duration is from 7 to 14 days.

 The primary endpoint is the clinical response rate of doripenem at the early follow-up visit.

 The patients will receive either doripenem or comparator for 7 to 14 days.

.

 Doripenem in the Treatment of Ventilator-Associated Pneumonia@highlight

The purpose of this study is to compare the clinical response rate of doripenem versus comparator in patients with ventilator-associated pneumonia (VAP).

